Herantis H2 2023: Presented positive phase I data - Redeye
Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.
ANNONS
Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.